(Circulation. 2008;117:2151-2159.)
© 2008 American Heart Association, Inc.
New Drugs and Technologies |
From the Bute Medical School, University of St Andrews, St Andrews, Fife, Scotland (A.R.B.), and the Clinical Sciences Research Institute, Warwick Medical School, University of Warwick, England (M.F.).
Correspondence to Anthony R. Butler, Bute Medical School, University of St. Andrews, St. Andrews, Fife, KY16 9ST, Scotland (e-mail arb3{at}st-andrews.ac.uk); or Martin Feelisch, Clinical Sciences Research Institute, Warwick Medical School, Gibbet Hill Rd, Coventry, CV4 7AL, England (e-mail mf@warwick.ac.uk).
| Abstract |
|---|
|
|
|---|
Key Words: cardiovascular diseases drugs history of medicine nitric oxide pharmacology
| Introduction |
|---|
|
|
|---|
| Discovery and Chemical Properties |
|---|
|
|
|---|
Nitrite is present at trace levels in soil, natural waters, and plant and animal tissues. In pure form, nitrite was first made by the prolific Swedish chemist Scheele14 working in the laboratory of his pharmacy in the market town of Köping. He heated potassium nitrate at red heat for half an hour and obtained what he recognized as a new "salt." The 2 compounds (potassium nitrate and nitrite) were characterized by Péligot15 and the reaction established as 2KNO3
2KNO2+O2.
The release of oxygen from a substance known to alchemists as "aerial niter" since the times of Paracelsus explains the role of nitrates in gunpowder, rocket propellants, and other explosives.16 Sodium nitrite rapidly gained importance in the development of organic chemistry during the 19th century, when it was discovered that nitrous acid (HNO2) reacts with aromatic amines (ArNH2) to produce diazonium ions,17 a highly important synthon for the dyestuffs industry and for synthetic organic chemistry generally: ArNH2+HNO2+H+
ArN=N++2H20.
The mechanism of such diazotization reactions has been subject to extensive study.18 Diazotization may be responsible, in part, for the carcinogenic role of nitrite under certain conditions, particularly in the context of drug-nitrite interactions.19
Nitric acid (HNO3) is a strong acid that is completely ionized at all biologically interesting pHs. Although nitrous acid (HNO2) is a weak acid, with a pKa of 3.15 (pKa is the pH at which the acid is 50% dissociated), it is also, at physiological pHs, completely dissociated, except in the stomach, on the surface of airways, within select cellular compartments (eg, the mitochondrial intermembrane space, endosomes, secretory vesicles, lysosomes, and other acidic organelles), and on the skin.
| Nitrite as a Vasodilator |
|---|
|
|
|---|
1 enzyme systems, possibly located in the vascular wall, that convert it into nitrite and subsequently to NO. One such enzyme, a mitochondrial aldehyde dehydrogenase, has been purified and partially characterized.29 However, the contribution of this or other enzyme systems to the overall vasodilation by these drugs is difficult to assess because multiple metabolic pathways appear to act in concert.30
In view of the range of organic nitrites and related compounds that act as vasodilators, it is not surprising that potassium and sodium nitrites were tested in this regard. In 1880, Reichert and Mitchell31 published a very full account of the biological action of potassium nitrite on humans and animals. At that time, the value of amyl nitrite in the treatment of angina was severely compromised by the short duration of its effect, so the search for an improved drug had begun. The effect of potassium nitrite on the nervous system, brain, spinal cord, pulse, arterial blood pressure, and respiration of healthy human volunteers was noted, as was the variability between individuals. The most significant observation was that even a small dose of <0.5 grains (
30 mg) given by mouth caused, at first, an increase in arterial blood pressure, followed by a moderate decrease. With larger doses, pronounced hypotension ensued. They also noted that potassium nitrite, however administered, had a profound effect on the appearance and oxygen-carrying capacity of the blood. They compared the biological action of potassium nitrite with that of amyl and ethyl nitrites and concluded, rather interestingly, that the similarity of action depends on the conversion of organic nitrites to nitrous acid. Observations similar to those of Reichert and Mitchell were made by Atkinson32 and Densham.33 Practicing physicians, including Hay34 and Leech,35 examined the therapeutic value of inorganic nitrites as hypotensive drugs and noted that, although of slower onset, their therapeutic effect lasts much longer, and they might be seen as superior drugs. They soon appeared in the Materia Medica of the time. In 1906, the drug supplier Squibb sold a 1-lb bottle of sodium nitrite (sodii nitris) for $1,36 and by the mid-1920s, an injectable solution of sodium nitrite became available (Nitroskleran, E. Tosse & Co, Hamburg, Germany) for the treatment of hypertension and vasospasm.37 Instructions for using sodium nitrite to treat angina are given in Martindales Additional Pharmacopoeia and in the US National Standard Dispensatory of 1905.38 A textbook on Materia Medica for medical students in 1921 gives details of the appropriate dose,39 but by the middle of the 20th century, its medicinal use had essentially ceased, largely because of adverse side effects. Blumgarten40 noted that sodium and potassium nitrites often caused nausea, belching, stomachache, and diarrhea. Although these side effects may have caused physicians to hesitate in prescribing sodium nitrite for angina, another event precipitated the fall of inorganic nitrite from favor (see below).
Interest in the vasodilator properties of nitrite enjoyed a renaissance with the notion that nitrite may be involved in the regulation of local blood flow after conversion to NO by nonenzymatic mechanisms41,42 and an oxygen-sensitive nitrite-reductase43 and S-nitrosothiol–synthase44 function of hemoglobin. Like NO, inhaled nebulized nitrite has been shown to be an effective pulmonary vasodilator45 and, along with organic nitrites,46 suggested for potential use in neonatal pulmonary hypertension. Although there is no doubt that appropriate pharmacological doses of nitrite can normalize elevated blood pressure,47 the question of whether physiological concentrations of nitrite are vasodilator active is still a matter of debate.48,49
| Conversion of Nitrite Into NO and NO-Related Products |
|---|
|
|
|---|
H2O+N2O3 and N2O3
NO+NO2. Solutions of acidified nitrite have been used successfully to generate NO and to induce vasorelaxation in isolated blood vessel studies,50 and the same reaction mechanism has been proposed to explain the biological action of nitrite.51,52 However, pHs at which this occurs are generally not found within living systems,53 with the exceptions mentioned above. On the other hand, the enzyme xanthine oxidoreductase converts nitrite into NO when oxygen levels are low, and this is a more likely course of action54 in the vascular system, at least under ischemic conditions. In fact, recent data suggest that hypoxic NO formation from nitrite is carried out by multiple enzyme systems10 and occurs in virtually all tissues and organs (Feelisch et al, unpublished data, 2006). Independently of its reduction to NO, nitrite is converted into NO-related products, including S-nitrosothiols and NO-heme species, at normal physiological pH and oxygen levels.55 Although it cannot be excluded that some of the biological effects of nitrite may be mediated by nitrite itself, it is fair to assume that most of the physiological and therapeutic actions of nitrite that require conversion into NO and NO-related products involve enzymatic catalysis.
| Nitrite as an Antidote for Cyanide and Hydrogen Sulfide Poisoning |
|---|
|
|
|---|
By the end of the 19th century, it was established that the toxicity of cyanide was due to interference with the process of cellular respiration.58 Keilin59 showed that cyanide reacts with the ferric heme of the enzyme cytochrome c oxidase, a vital link between the tricarboxylic acid cycle and formation of metabolic water causing inhibition of mitochondrial respiration. Because cyanide also reacts with methemoglobin,60 it should be possible to prevent the reaction of cyanide with cytochrome c oxidase by massively increasing the concentration of methemoglobin in the blood. Nitrite oxidizes the central iron atom of hemoglobin from the ferrous (Fe2+) to the ferric (Fe3+) state, producing methemoglobin, and is therefore a potential antidote for cyanide poisoning. The clinical use of nitrite in this setting was first proposed by Hug61 and is now universally used. Sodium thiosulfate also is included in the antidote to provide a source of sulfur to aid the conversion of cyanide into thiocyanate by rhodanese. The first cases of acute cyanide poisoning in humans to be treated with nitrite and thiosulfate were reported in 1934. One patient had ingested 5 g potassium cyanide but recovered after being given 1.5 g sodium nitrite and 18 g sodium thiosulfate.62 In many countries, nitrite is part of the cyanide antidote kit. Nowadays, patients are given an ampoule of amyl nitrite by inhalation or an intravenous injection of 3% sodium nitrite, followed by a slow injection of 50% sodium thiosulfate.63
Although formation of methemoglobin is generally accepted as the explanation of the efficacy of nitrite as an antidote, evidence suggests that this is not the complete explanation.64,65 There may be alternative or additional routes whereby nitrite detoxifies, but no details are available.66 Compounds that promote NO release in vivo (like bradykinin) modify cyanide toxicity. Whether this is an alternative mode of action of nitrite in detoxification or just another source of nitrite from endogenous NO is, at this time, difficult to assess.
Nitrite also is an efficacious antidote to poisoning by hydrogen sulfide (H2S), an occupational hazard with high lethality and long-term neurological sequelae in survivors. Like NO and CO, low concentrations of H2S are produced endogenously and have vasodilator properties, but the physiological significance of its formation is currently unknown.67 Supraphysiological concentrations of sulfide, as experienced after H2S inhalation, lead to rapid inhibition of mitochondrial respiration by reversible binding to the central iron atom of cytochrome c oxidase in place of oxygen, explaining why H2S poisoning shares many similarities with cyanide intoxication.68 Nitrite administration, which is superior to that of oxygen alone69 and often is combined with hyperbaric oxygen therapy, is most effective when given immediately after H2S exposure.70 It is thought to act via induction of methemoglobinemia and subsequent binding of hydrosulfide anions (HS–) to the oxidized blood pigment, leading to inhibition of cytochrome c oxidase and reinstitution of aerobic respiration in the tissues. Although this mode of action appears reasonable, the rather slow rate of methemoglobin formation by nitrite is inconsistent with the rapid recovery typically observed in the clinical setting, suggesting, as with the treatment of cyanide poisoning, the involvement of additional mechanisms. Although nitrite has been known for many years to have protective and antidotal effects against experimental sulfide poisoning in rodents,71 nitrite administration for H2S intoxication was introduced into human therapy only in the mid-1970s.72 The recommended dosage regimen for nitrite in sulfide intoxication is identical to that established for the treatment of cyanide poisoning, ie, initiation with inhalations of amyl nitrite followed by intravenous injection of 10 mL of a 3% solution of sodium nitrite.73
| Other Medical Uses of Inorganic Nitrite |
|---|
|
|
|---|
| Acidified Nitrite |
|---|
|
|
|---|
The effectiveness of acidified nitrite in killing antibiotic-resistant Pseudomonas bacteria might offer a possibility to eradicate a major cause for chronic lung infections in cystic fibrosis patients,79 provided a safe mode of administration can be found. The antimicrobial properties of NO can be exploited by dermal application of creams containing nitrite and an acidifying agent, eg, ascorbic acid, to treat a number of skin diseases.80 The same concept has been demonstrated to increase microcirculatory blood flow in Raynaud patients81,82 and to accelerate wound healing.83 Although the effects of acidified nitrite are typically ascribed to the generation of NO, the possibility that part of the nitrite applied is absorbed and converted into NO-related products in the tissue cannot be excluded.
| Use of Inorganic Nitrate in Medicine |
|---|
|
|
|---|
Niter occurs in natural deposits in desert regions. Fairly large amounts are found in the northwestern provinces of China, and it was well known to early Chinese alchemists. They called it xiao shi (solve stone), and it was first recognized in the 4th century CE. It was a component of some of the elixirs of immortality concocted by Daoist savants as they searched for a means of realizing the Daoist ideal of life without death.84 Entirely by chance, they mixed it with sulfur and charcoal and thus created gunpowder, which was used by the Chinese not only for fireworks but also for civil engineering and warfare. The first printed formula for gunpowder occurs in a Chinese manual of war that appeared in 1044 CE.
One of the oldest accounts of the use of niter in Chinese medicine is as a treatment for what appears to be angina in an 8th century Chinese manuscript uncovered at the Buddhist grotto of Dunhuang.85 The patient is instructed to take niter, hold it under the tongue for a time, and then swallow the saliva. The significance of the instructions is that under the tongue, even in a healthy mouth, nitrate-reducing bacteria convert some of the nitrate into nitrite.77,86 So, if the patient follows the physicians instructions fully, he or she will be taking in nitrite, known to be a treatment for the alleviation of anginal pain.
Arab physicians were among the most advanced of the medieval period, but there is no mention of niter in a book on cardiac drugs by Avicenna, born 980 CE. The first extant Arabic mention of niter occurs in a book by Kitab al-Jamifi al-Adwiya al-Mufrada (Book of the Assembly of Medical Simples) finished by Abu-Muhammad al-Malaqi Ibn al-Baitar around CE 1240. Niter was called Thalji al-Sin (Chinese snow), indicating the contact between Chinese and Arab civilizations. It was about this time that Arabs started to use niter in gunpowder and as a component of prescriptions.
Niter does not occur naturally to any great extent in Europe, and the efficacious use of niter in early European medicine is easier to understand if one realizes how the niter was produced. When gunpowder became known in Europe (Roger Bacon mentions it in 1240 CE), there was enormous demand for niter, and much was shipped to Europe from India, where it occurs in natural deposits. But, the demand outstripped supply, and indigenous manufacture was started. It was made in plantations or "nitriaries," particularly in France and Germany. Natural conditions were simulated by exposing heaps of decaying organic matter mixed with lime to atmospheric action.87 Nitrates appeared as efflorescences and were converted into potassium salt by reaction with potassium carbonate (potash). Two groups of bacteria are responsible for this process: Nitrosomonas convert ammonia into nitrite, and Nitrobacter convert nitrite into nitrate.88 It is quite possible that niter from nitriaries contained some nitrite, thus giving it medicinal value. This is unlikely in niter from natural deposits because they are old and aerial oxidation will, over time, convert all the nitrite into nitrate. So, the 8th century Chinese physician mentioned previously had to instruct the patient on how to generate nitrite, but European physicians of the 14th to 17th centuries, using niter from a different source, could prescribe it without further refinement because nitrite was there already.
However, such a prescription was rather hit-or-miss in that the amount of nitrite present was a matter of chance. In one of the most comprehensive accounts of the use of niter, methods of making it more effective are described. The book, by Challoner, was printed in London in 1584 and entitled A Short Discourse of the Most Rare and Excellent Vertue of Nitre.89 The spelling of the English is idiosyncratic (rather like that of modern students) because spelling was not fully standardized until the publication of Johnsons dictionary in 1775. Challoners book is concerned mainly with the value of niter in treating various dermatological conditions ("diseases of the skinne"), including "tawnie steynings, freckles, duskness and flegmatike evaporations." It will, he claims, "restore the skinne and complexion to the native bewtie." The key to understanding this claim lies in the first section of the book in which the author tells his readers how to make niter more effective ("yet more sharpe and subtile"). He describes 3 ways, all involving heating (called "calcination" by Challoner). Heat, of course, converts some of the niter into potassium nitrite, and so, without realizing it, Challoner anticipated the discovery of potassium nitrite by Scheele by nearly 200 years. As discussed above, nitrite has an antibacterial effect and accelerates wound healing, hence its effectiveness on infected skin blemishes ("skales, scrabbes, skurffe, dandruffe, pimples, tetters, bytes" and so on). Naturally occurring nitrite in saliva has the same effect and explains, in part, why most animals instinctively lick a wound.90
Challoner does not stop with the application of niter to the skin. He claims that it can be used "for uncumbring and clensing of the lunges" and for the "remedie of hoarnesses, olde coughe and toughe coughe, weising in the windpipes," and so on. For this use, he suggests making the niter into a pill and then "hold one of those pilles lounge under the tongue, to mixe thereof as much as may be with the moisture of the mouth ... and lastlie swallow it," a procedure curiously reminiscent of the Chinese prescription and anticipating some of the work of Lundberg et al.77
| Nitrate and the Treatment of Lung Diseases |
|---|
|
|
|---|
In addition to its use in asthma, sodium nitrate was given orally to treat chronic bronchitis.96 It is unclear whether the apparent effectiveness of this treatment was secondary to its conversion to nitrite causing bronchial relaxation and antibacterial effects or due to an effect of nitrate itself.
| Nitrates as Diuretics |
|---|
|
|
|---|
Extensive animal and human studies by Keith et al102 confirmed the superiority of the ammonium over the sodium salt of nitrate. They also demonstrated that nitrates can potentiate the effects of other diuretics and that toxic symptoms are remarkably rare, even when administered in doses of 10 to 15 g daily for several weeks. Thus, ammonium nitrate was introduced as a new, more effective diuretic in 1926 and was used with great success to treat various forms of edema in North America, particularly at the Mayo Clinic. After a time of exaggerated emphasis on possible toxic effects of nitrates during the preceding 2 decades, which led physicians to use lower, inadequate doses, it looked as though ammonium nitrate was here to stay as the diuretic of choice. What had triggered the fear of inducing severe cyanosis when potassium or sodium nitrate was used as a diuretic before was the toxicity associated with the use of massive amounts of bismuth subnitrate for diagnostic purposes,103 which is somewhat surprising because the toxicity of large amounts of nitrate was well known for a long time.104 Concerns about the safety of nitrates reached a new height with the appearance of case reports about transient methemoglobinemia after administration of ammonium nitrate.105,106 The reasons for these rare complications (which disappeared on discontinuation of nitrate therapy in most cases) remain unclear but may have been due to contamination of the nitrate salt with nitrite, renal insufficiency causing elevated circulating levels of nitrate, or gastrointestinal disorders with enhanced reduction of nitrate to nitrite by the bacterial gut flora.107 With alternative diuretics in the form of organic mercurials available, the therapeutic use of nitrates as diuretics was abandoned by the mid-1930s.
| Nitrate in Other Medicinal Preparations |
|---|
|
|
|---|
| Conclusions and Outlook |
|---|
|
|
|---|
5% of all ingested and endogenously produced nitrate eventually ends up as nitrite in the stomach, as pointed out by Archer109 (so far about "intelligent design"). Despite the critical voices, the image of nitrite and nitrate remains stigmatized. What appears to have the greatest potential to change our current perception of the risk and value of nitrite and nitrate is the most recent emergence of data on the physiological and pharmacological effects of relatively low concentrations/doses of nitrite. Previously considered a biologically inert oxidative decomposition product of NO, nitrite has been proposed to be a signaling molecule in its own right.55 Given its propensity for conversion into NO and related species, unequivocal evidence for this role may be difficult to provide unless nitrite-specific signaling pathways are identified. Although speculative, it is possible that the nitrite-based reaction channels of contemporary mammalian cells are a vestige of earlier bacterial pathways and that the evolutionarily more recent L-arginine/NO pathway uses signaling cascades originally evolved for nitrite, not the other way round. Regardless, surprisingly low amounts of nitrite have been demonstrated to exert potent cytoprotective effects against ischemia/reperfusion-related tissue damage in vivo,10,11 an action possibly mediated by modulation of mitochondrial function.113 Nitrate, which has been proposed to contribute to the health-promoting effects of the Mediterranean diet,114 has been demonstrated to inhibit platelet aggregation,115 to mildly lower blood pressure,116 to enhance gastric mucosal defense mechanisms,107 and to reduce the oxygen cost of exercise.117 The last is perhaps one of the most surprising of the more recent findings across the spectrum of nitrate actions. This particular observation may explain why an enhanced production of NO, which not only elevates blood flow and thus oxygen transport to tissues but leads to increased levels of circulating nitrite and nitrate, is crucial for the adaptation of life to the chronic hypoxia experienced at high altitude.118 Taken together, these results have shifted the attention away from toxic and vasodilator properties to a focus on metabolic effects. Moreover, they make one wonder to what extent inorganic nitrate may contribute to the effectiveness of organic nitrates in the setting of heart failure, for example.
Although efforts are underway to assess the potential usefulness of inorganic nitrite in a number of clinical research studies at the US National Institutes of Health, none of these are likely to whet the appetite of the pharmaceutical industry to invest substantial amounts of money into drug development because not only are intellectual property claims related to simple inorganic compounds legally difficult to defend but the material itself is cheap and readily available. The situation may change if medicinal chemists come up with new prodrugs that allow targeted delivery of nitrite to specific tissues or organs or if nitrite/nitrate is intelligently used as an adjuvant to current therapeutics. Which of the many facets of nitrite and nitrate action is likely to form the basis for future pharmaceutical exploitation is difficult to predict at present. Although rational approaches to the pharmacological treatment of medical problems have a tendency to ridicule the wisdom of century-old folk medicine and to condemn the alchemists doing as quackery, there is much to learn from the past. In reviewing the therapeutic use of nitrite and nitrate over centuries, it appears that some of the potential that these simple compounds may hold for medical use have not been realized, often because the basis for some unwanted drug effects was not understood and thus could not be controlled at the time. But, even if the scare factor continues to dominate mainstream thinking, there is an obvious need for a careful reassessment of the health risks of nitrite and nitrate. If initiated soon, such activity may provide the necessary "activation energy" to overcome the fear and to stimulate the development of new therapeutic principles that use pathways regulated by nitrite and nitrate.
| Acknowledgments |
|---|
This work was supported by funds from the Guthrie Trust (a travel grant for visiting the Wellcome History of Medicine Library in London to Dr Butler) and the Medical Research Council (Strategic Appointment Scheme to Dr Feelisch).
Disclosures
None.
| References |
|---|
|
|
|---|
2. Green LC, Tannenbaum SR, Goldman P. Nitrate synthesis in the germfree and conventional rat. Science. 1981; 212: 56–58.
3. Green LC, Ruiz de Luzuriaga K, Wagner DA, Rand W, Istfan N, Young VR, Tannenbaum SR. Nitrate biosynthesis in man. Proc Natl Acad Sci U S A. 1981; 78: 7764–7768.
4. Griess P. Über Metadiamidobenzol als Regens auf Saltpetrige Säure. Chem Ber. 1878; 11: 624–627.
5. Cruickshank J, Moyes JM. The presence and significance of nitrites in urine. BMJ. 1914; 2: 712–713.
6. Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature. 1988; 333: 664–666.[CrossRef][Medline] [Order article via Infotrieve]
7. Marletta MA, Yoon PS, Iyengar R, Leaf CD, Wishnok JS. Macrophage oxidation of L-arginine to nitrite and nitrate: nitric oxide is an intermediate. Biochemistry. 1988; 27: 8706–8711.[CrossRef][Medline] [Order article via Infotrieve]
8. Gladwin MT, Shelhammer JH, Schechter AN, Pease-Fye ME, Waciawiw MA, Panza JA, Ognibene FP, Cannon RO. Role of circulating nitrite and S-nitrosohemoglobin in the regulation of regional blood flow in humans. Proc Natl Acad Sci U S A. 2000; 97: 11482–11487.
9. Dejam A, Hunter CJ, Tremonti C, Pluta RM, Hon YY, Grimes G, Partovi K, Pelletier MM, Oldfield EH, Cannon RO, Schechter AN, Gladwin MT. Nitrite infusion in humans and nonhuman primates: endocrine effects, pharmacokinetics, and tolerance formation. Circulation. 2007; 116: 1821–1831.
10. Lundberg JO, Weitzberg E, Gladwin MT. The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov. 2008; 7: 156–167.[CrossRef][Medline] [Order article via Infotrieve]
11. Dezfulian C, Raat N, Shiva S, Gladwin MT. Role of the anion nitrite in ischemia-reperfusion cytoprotection and therapeutics. Cardiovasc Res. 2007; 75: 327–338.
12. Ingested Nitrates and Nitrites. Lyon, France: International Agency for Research on Cancer; 2007. IARC Monographs volume 94. Available at: http://monographs.iarc.fr/ENG/Meetings/94-nitratenitrite.pdf. Accessed September 4, 2007.
13. Barnum DW. Some history of nitrates. J Chem Ed. 2003; 80: 1393–1396.
14. Scheele CW. Chemische Abhandlung von der Luft und dem Feuer. Upsala, Sweden: M. Swederus; 1777.
15. Péligot E. Sur lacide hypoazotique et sur lacide azoteux. Ann Chim Phys. 1841; 2: 58–68.
16. Debus AG. The Paracelsian aerial niter. Isis. 1964; 55: 43–61.[CrossRef]
17. Williams DLH. Nitrosation Reactions and the Chemistry of Nitric Oxide. London, UK: Elsevier; 2004.
18. Ridd JH. Nitrosation, diazotisation and deamination. Quart Rev. 1961; 15: 418–436.[CrossRef]
19. Magee PN, Barnes JM. The production of primary hepatic malignant tumours in the rat by feeding dimethylnitsoamine. Br J Cancer. 1956; 10: 114–122.[Medline] [Order article via Infotrieve]
20. Butter W. A Treatise on the Disease Commonly Called Angina Pectoris. London, UK: J. Johnson; 1791.
21. Brunton TL. On the use of nitrite of amyl in angina pectoris. Lancet. 1867; 2: 97–98.
22. Murrell W. Nitro-glycerine as a remedy for angina pectoris. Lancet. 1879; 1: 80–81, 113–115.
23. Phillips CDF. Materia Medica, Pharmacology and Therapeutics Inorganic Substances. 2nd ed. London, UK: J&A Churchill; 1894.
24. White WH. Materia Medica Pharmacy, Pharmacology and Therapeutics. London, UK: J&A Churchill; 1899.
25. Fye WB. Nitroglycerin: a homeopathic remedy. Circulation. 1986; 73: 21–29.
26. Harrington M. Hypotensive Drugs. London, UK: Pergamon Press; 1956.
27. Bellamy A. The development of nitroglycerine as an explosive. Atti del convegno in celerazione del centenario della morte di Ascanio Sobrero. Turín, Italy: University of Turín; 1989.
28. Fant K. Alfred Nobel: En Biografi. Stockholm, Sweden: Norstedts Förlag; 1991: 302.
29. Chen Z, Zhang J, Stamler JS. Identification of the enzymatic mechanism of nitroglycerine bioactivation. Proc Natl Acad Sci U S A. 2002; 99: 8306–8311.
30. Janero DR, Bryan NS, Saijo F, Dhawan V, Schwalb DJ, Warren MC, Feelisch M. Differential nitros(yl)ation of blood and tissue constituents during glyceryl trinitrate biotransformation in vivo. Proc Natl Acad Sci U S A. 2004; 101: 16958–16963.
31. Reichert ET, Mitchell SW. On the physiological action of potassium nitrite. Am J Med Sci. 1880; 156: 158–180.
32. Atkinson GA. The physiology of the nitrites and nitro-glycerine. J Anat Physiol. 1888; 22: 225–239, 351–371.[Medline] [Order article via Infotrieve]
33. Densham B. The adjuvant action of the lactate ion on the vaso-dilator effect of sodium nitrite. J Physiol. 1927; 63: 175–179.
34. Hay M. Nitrite of sodium in the treatment of angina pectoris. Practitioner. 1883; 30: 170–194.
35. Leech DJ. On the duration of the action of medicines. BMJ. 1885; 2: 1005–1011.
36. Squibbs Materia Medica. New York, NY: E.R. Squibb & Sons; 1906.
37. Deusch G, Liepelt A. Die Hautkapillaren beim arteriellen Hochdruck und ihre Beeinflussung durch Nitrite. Deutsches Arch Klin Med. 1928; 160: 207–211.
38. Hare HA, Caspari C, Rusby HH. National Standard Dispensatory. Philadelphia, Pa: Lea Bros & Co; 1905.
39. Bennett RG. Materia Medica and Pharmacy for Medical Students. London, UK: HK Lewis; 1921.
40. Blumgarten AS. Textbook of Materia Medica and Therapeutics. New York, NY: MacMillan; 1934.
41. Modin A, Bjorne H, Herulf M, Alving K, Weitzberg E, Lundberg JO. Nitrite-derived nitric oxide: a possible mediator of "acidic-metabolic" vasodilation. Acta Physiol Scand. 2001; 171: 9–16.[CrossRef][Medline] [Order article via Infotrieve]
42. Zweier JL, Wang P, Samouilov A, Kuppusamy P. Enzyme-independent formation of nitric oxide in biological tissues. Nat Med. 1995; 1: 804–809.[CrossRef][Medline] [Order article via Infotrieve]
43. Cosby K, Partovi KS, Crawford JH, Patel RP, Reiter CD, Martyr S, Yang BK, Waclawiw MA, Zalos G, Xu X, Huang KT, Shields H, Kim-Shapiro DB, Schechter AN, Cannon RO, Gladwin MT. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat Med. 2003; 9: 1498–1505.[CrossRef][Medline] [Order article via Infotrieve]
44. Angelo M, Singel DJ, Stamler JS. An S-nitrosothiol (SNO) synthase function of hemoglobin that utilizes nitrite as a substrate. Proc Natl Acad Sci U S A. 2006; 103: 8366–8371.
45. Hunter CJ, Dejam A, Blood AB, Shields H, Kim-Shapiro DB, Machado RF, Tarekegn S, Mulla N, Hopper AO, Schechter AN, Power GG, Gladwin MT. Inhaled nebulized nitrite is a hypoxia-sensitive NO-dependent selective pulmonary vasodilator. Nat Med. 2004; 10: 1122–1127.[CrossRef][Medline] [Order article via Infotrieve]
46. Moya MP, Gow AJ, Califf RM, Goldberg RN, Stamler JS. Inhaled ethyl nitrite gas for persistent pulmonary hypertension of the newborn. Lancet. 2002; 360: 141–143.[CrossRef][Medline] [Order article via Infotrieve]
47. Beier S, Classen HG, Loeffler K, Schumacher E, Thöni H. Antihypertensive effect of oral nitrite uptake in the spontaneously hypertensive rat. Arzneimittelforschung. 1995; 45: 258–261.[Medline] [Order article via Infotrieve]
48. Lauer T, Preik M, Rassaf T, Strauer BE, Deussen A, Feelisch M, Kelm M. Plasma nitrite rather than nitrate reflects regional endothelial nitric oxide synthase activity but lacks intrinsic vasodilator action. Proc Natl Acad Sci U S A. 2001; 98: 12814–12819.
49. Dalsgaard T, Simonsen U, Fago A. Nitrite-dependent vasodilation is facilitated by hypoxia and is independent of known NO-generating nitrite reductase activities. Am J Physiol Heart Circ Physiol. 2007; 292: H3072–H3078.
50. Furchgott RF, Bhadrakom. Reactions of strips of rabbit aorta to epinephrine, isopropylarterenol, sodium nitrite and other drugs. J Pharmacol Exp Ther. 1953; 108: 129–143.
51. Farrari R, Cargoni A, Bernocchi P, Pasini E, Curello S, Ceconi C, Ruigrok TJC. Metabolic adaptation during a sequence of no-flow and low-flow ischemia. Circulation. 1996; 94: 2587–2596.
52. Samlouilov A, Kuppusamy P, Zweier JI. Evaluation of the magnitude and rate of nitric oxide production from nitrite in biological systems. Arch Biochem Biophys. 1998; 357: 1–7.[CrossRef][Medline] [Order article via Infotrieve]
53. Butler AR, Ridd JH. Formation of nitric oxide from nitrous acid in ischemic tissue and skin. Nitric Oxide. 2004; 10: 20–24.[Medline] [Order article via Infotrieve]
54. Webb A, Bond R, McClean P, Uppal R, Benjamin N, Ahluwalia A. Reduction of nitrite to nitric oxide during ischemia protects against myocardial ischemic-reperfusion damage. Proc Natl Acad Sci U S A. 2004; 101: 13683–13688.
55. Bryan NS, Fernandez BO, Bauer SM, Garcia-Saura MF, Milsom AB, Rassaf T, Maloney RE, Bharti A, Rodriguez J, Feelisch M. Nitrite is a signaling molecule and regulator of gene expression in mammalian tissues. Nat Chem Biol. 2005; 1: 290–297.[CrossRef][Medline] [Order article via Infotrieve]
56. Granville AB. Further Observations on the Internal Use of the Hydro-cyanic (Prussic) Acid. London, UK: Butgess & Hill; 1820.
57. Magendie F. Sur lemploi de lacide prussique dans le traitement de plusieurs maladies de poitrine, et particulièrement dans la phtisie pulmonaire. Ann Chim Phys. 1817; 6: 347–360.
58. Commoner B. Cyanide inhibition as a means of elucidating the mechanism of cellular respiration. Bio Rev (Cambridge Phil Soc). 1940; 15: 168–201.[CrossRef]
59. Keilin D, Hartree EF. Cytochrome c and cytochrome oxidase. Proc Royal Soc London Series B. 1939; 127: 167–191.
60. Kobert R. Über Cyanmethämoglobin und den Nachweis der Blausäure. Stuttgart, Enke: Germany; 1891; Cited by: Keilin D. The History of Cell Respiration and Cytochrome. Cambridge, UK: CUP; 1966.
61. Hug E. Accion del nitrite de sodio del hiposulfate de sodio en el tratamiento de la intoxication provocada por el ciannuro de potassio en al conejo. Rev Soc Argent Biol. 1932; 3: 270–276.
62. Viana C, Cagnoli H, Cendan J. Laction du nitrite de sodium dans lintoxication par les cyanures. C R Seances Soc Biol Fil. 1934; 115: 1649–1651.
63. Matthew H, Lawson AAH. Treatment of Common Acute Poisonings. 4th ed. Edinburgh, Scotland: Churchill Livingstone; 1979.
64. Cucinell SA, Groff WA, Vick JA, Weger N. Treatment of cyanide poisoning. Fed Proc. 1974; 33: 234. Abstract.
65. Isom GE, Way JL. Lethality of cyanide in the absence of inhibition of liver cytochrome oxidase. Biochem Pharmacol. 1976; 25: 605–608.[CrossRef][Medline] [Order article via Infotrieve]
66. Baskin SI, Froehlich HL, Groff WA. The dissociation of reversal of cyanide (CN) toxicity and methemoglobin formation by nitrite (N) in the isolated heart. Fed Proc. 1986; 45: 196. Abstract.
67. Ali MY, Ping CY, Mok YY, Ling L, Whiteman M, Bhatia M, Moore PK. Regulation of vascular nitric oxide in vitro and in vivo; a new role for endogenous hydrogen sulphide? Br J Pharmacol. 2006; 149: 625–634.[CrossRef][Medline] [Order article via Infotrieve]
68. Smith RP, Gosselin RE. Hydrogen sulfide poisoning. J Occup Med. 1979; 21: 93–97.[CrossRef][Medline] [Order article via Infotrieve]
69. Smith RP, Kruszyna R, Kruszyna H. Management of acute sulfide poisoning: effects of oxygen, thiosulfate, and nitrite. Arch Environ Health. 1976; 31: 166–169.[Medline] [Order article via Infotrieve]
70. Beck JF, Bradbury CM, Connors AJ, Donini JC. Nitrite as antidote for acute hydrogen sulfide intoxication? Am Ind Hyg Assoc J. 1981; 42: 805–809.[Medline] [Order article via Infotrieve]
71. Scheler W, Kabisch R. On the antagonistic alteration of acute H2S poisoning in mice with methemoglobin forming agents. Acta Biol Med Ger. 1963; 11: 194–199.[Medline] [Order article via Infotrieve]
72. Stine RJ, Slosberg B, Beacham BE. Hydrogen sulfide intoxication: a case report and discussion of treatment. Ann Intern Med. 1976; 85: 756–758.[CrossRef][Medline] [Order article via Infotrieve]
73. Chen KK, Rose CL. Nitrite and thiosulfate therapy in cyanide poisoning. JAMA. 1952; 149: 113–119.
74. Law WT. Sodium nitrite in the treatment of epilepsy. Practitioner. 1882; 28: 420–424.
75. Ringer S, Murrell W. Nitrite of sodium as a toxic agent. Lancet. 1883; 2: 766–767.
76. van Grinsven HJM, Ward MH, Benjamin N, de Kok TM. Does the evidence about health risks associated with nitrate ingestion warrant an increase of the nitrate standard for drinking water? Environ Health. 2006; 5: 26–30.[CrossRef][Medline] [Order article via Infotrieve]
77. Lundberg JO, Weitzberg E, Cole JA, Benjamin N. Nitrate, bacteria and human health. Nat Rev Microbiol. 2004; 2: 593–602.[CrossRef][Medline] [Order article via Infotrieve]
78. Weller R, Pattullo S, Smith L, Golden M, Ormerod A, Benjamin N. Nitric oxide is generated on the skin surface by reduction of sweat nitrate. J Invest Dermatol. 1996; 107: 327–331.[CrossRef][Medline] [Order article via Infotrieve]
79. Yoon SS, Coakley R, Lau GW, Lymar SV, Gaston B, Karabulut AC, Hennigan RF, Hwang SH, Buettner G, Schurr MJ, Mortensen JE, Burns JL, Speert D, Boucher RC, Hassett DJ. Anaerobic killing of mucoid Pseudomonas aeruginosa by acidified nitrite derivatives under cystic fibrosis airway conditions. J Clin Invest. 2006; 116: 436–446.[CrossRef][Medline] [Order article via Infotrieve]
80. Weller R, Price RJ, Ormerod AD, Benjamin N, Leifert C. Antimicrobial effect of acidified nitrite on dermatophyte fungi, Candida and bacterial skin pathogens. J Appl Microbiol. 2001; 90: 648–652.[CrossRef][Medline] [Order article via Infotrieve]
81. Tucker AT, Pearson RM, Cooke ED, Benjamin N. Effect of nitric-oxide-generating system on microcirculatory blood flow in skin of patients with severe Raynauds syndrome: a randomised trial. Lancet. 1999; 354: 1670–1675.[CrossRef][Medline] [Order article via Infotrieve]
82. Khan F, Pearson RJ, Newton DJ, Belch JJF, Butler AR. Chemical synthesis and microvascular effects of new nitric oxide donors in humans. Clin Sci. 2003; 195: 577–584.
83. Weller R, Finnen MJ. The effects of topical treatment with acidified nitrite on wound healing in normal and diabetic mice. Nitric Oxide. 2006; 15: 395–399.[CrossRef][Medline] [Order article via Infotrieve]
84. Tsao TC, Ho PY, Needham J. An early mediaeval Chinese alchemical text on aqueous solutions. Ambix. 1959; 7: 122–155.[Medline] [Order article via Infotrieve]
85. Butler AR, Moffett J. In: Lo EY, Cullen C, eds. Medieval Chinese Medicine: The Dunhuang Medical Manuscripts. London, UK: Routledge; 2004.
86. Duncan C, Dougall H, Johnson P, Green S, Brogan R, Leifert C, Smith L, Golden M, Benjamin N. Chemical generation of nitric oxide from the enterosalivary circulation of dietary nitrate. Nat Med. 1995; 1: 546–551.[CrossRef][Medline] [Order article via Infotrieve]
87. Pietsch G. Dissertation sur la Generation du Nitre. Berlin, Germany: Chez Haude et Spener; 1746.
88. Postgate J. Nitrogen Fixation. 3rd ed. Cambridge, UK: CUP; 1998.
89. Challoner T. A Short Discourse on the Most Rare and Excellent Vertue of Nitre. London, UK; G Dewes; 1584.
90. Benjamin N, Pattullo S, Weller R, Smith L, Omerod A. Wound licking and nitric oxide. Lancet. 1997; 349: 1776.[Medline] [Order article via Infotrieve]
91. Pearse F. The treatment of paroxysmal nerve disorders. Practitioner. 1891; 46: 29–32.
92. Cassan S. Relieving affections of the lungs or chest. UK Patent 2524; 1868.
93. Encyclopædia Britannica. Vol. XXIV, 11th ed. Cambridge, UK: CUP; 1911: 94.
94. Dispensatory of the United States of America. 21st ed. Philadelphia, Pa: JB Lippincott; 1926.
95. Oza TM. Thermal decomposition of sodium and potassium nitrites. J Indian Chem Soc. 1945; 22: 173–180.
96. Ziment I. History of the treatment of chronic bronchitis. Respiration. 1991; 58 (suppl 1): 37–42.[Medline] [Order article via Infotrieve]
97. Willis T. Pharmaceutice Rationalis: Or an Exercitation of the Medicines in Humane Bodies. London, UK; T. Dring, C. Harper, and J. Leigh; 1697.
98. Jörg JCG. Materialien zu einer künftigen Heilmittellehre durch Versuche der Arzneyen an gesunden Menschen gewonnen u. gesammelt. Leipzig, Germany: Carl Cnobloch; 1825.
99. Hiatt EP. Comparison of the diuretic effects of nitrate salts with other diuretic agents. Am J Physiol. 1957; 189: 173–176.
100. Cahn A. Die Magenverdauung im Chlorhunger. Ztschr F Physiol Chem. 1886; 10: 522–535.
101. Greene I, Hiatt EP. Renal excretion of nitrate and its effect on excretion of sodium and chloride. Am J Physiol. 1954; 180: 179–182.
102. Keith NM, Whelan M, Bannick EG. The action and excretion of nitrates. Arch Intern Med. 1930; 46: 797–832.
103. Beck EG. Toxic effects from bismuth subnitrate: with reports of cases to date. JAMA. 1909; 52: 14–18.
104. Alexander W. William Alexanders Medizinische Versuche und Erfahrungen. Leipzig, Germany: A.d.E.; 1773.
105. Eustermann GB, Keith NM. Transient methemoglobinemia following administration of ammonium nitrate. Med Clin North Am. 1929; 12: 1489–1496.
106. Tarr L. Transient methemoglobinemia due to ammonium nitrate. Arch Intern Med. 1933; 51: 38–44.
107. Petersson J, Phillipson M, Jansson EA, Patzak A, Lundberg JO, Holm L. Dietary nitrate increases gastric mucosal blood flow and mucosal defense. Am J Physiol Gastrointest Liver Physiol. 2007; 292: G718–G724.
108. Humphreys SD, Routledge PA. The toxicology of silver nitrate. Adverse Drug React Toxicol Rev. 1998; 17: 115–143.[Medline] [Order article via Infotrieve]
109. Archer DL. Evidence that ingested nitrate and nitrite are beneficial to health. J Food Prot. 2002; 65: 872–875.[Medline] [Order article via Infotrieve]
110. Addiscott TM, Benjamin N. Are you taking your nitrate? Food Sci Technol Today. 2000; 14: 59–61.
111. LHirondel JJ, LHirondel J-L. Nitrate and Man: Toxic, Harmless or Beneficial? Oxford, UK: CABI Publishing; 2002.
112. Suschek CV, Schewe T, Sies H, Kroncke KD. Nitrite, a naturally occurring precursor of nitric oxide that acts like a "prodrug." Biol Chem. 2006; 387: 499–506.[CrossRef][Medline] [Order article via Infotrieve]
113. Shiva S, Sack MN, Greer JJ, Duranski M, Ringwood LA, Burwell L, Wang X, Macarthur PH, Shoja A, Raghavachari N, Calvert JW, Brookes PS, Lefer DJ, Gladwin MT. Nitrite augments tolerance to ischemia/reperfusion injury via the modulation of mitochondrial electron transfer. J Exp Med. 2007; 204: 2089–2102.
114. Lundberg JO, Feelisch M, Bjorne H, Jansson EA, Weitzberg E. Cardioprotective effects of vegetables: is nitrate the answer? Nitric Oxide. 2006; 15: 359–362.[CrossRef][Medline] [Order article via Infotrieve]
115. Richardson G, Hicks SL, OByrne S, Frost MT, Moore K, Benjamin N, McKnight GM. The ingestion of inorganic nitrate increases gastric S-nitrosothiol levels and inhibits platelet function in humans. Nitric Oxide. 2002; 7: 24–29.[CrossRef][Medline] [Order article via Infotrieve]
116. Larsen FJ, Ekblom B, Sahlin K, Lundberg JO, Weitzberg E. Effects of dietary nitrate on blood pressure in healthy volunteers. N Engl J Med. 2006; 355: 2792–2793.
117. Larsen FJ, Weitzberg E, Lundberg JO, Ekblom B. Effects of dietary nitrate on oxygen cost during exercise. Acta Physiol. 2007; 191: 59–66.[CrossRef]
118. Erzurum SC, Ghosh S, Janocha AJ, Xu W, Bauer S, Bryan NS, Tejero T, Hemann C, Hille R, Stuehr DJ, Feelisch M, Beall CM. Higher blood flow and circulating nitric oxide products offset high-altitude hypoxia among Tibetans. Proc Natl Acad U S A. 2007; 104: 17593–17598.
This article has been cited by other articles:
![]() |
N. G Hord, Y. Tang, and N. S Bryan Food sources of nitrates and nitrites: the physiologic context for potential health benefits Am. J. Clinical Nutrition, July 1, 2009; 90(1): 1 - 10. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. B Katan Nitrate in foods: harmful or healthy? Am. J. Clinical Nutrition, July 1, 2009; 90(1): 11 - 12. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2008 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |